

Form PTO-1449 (modified)	Atty. Docket No. DEBE:053US	Serial No. 10/527,785
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Marco Cattaruzza Markus Hecker	
	Filing Date: March 11, 2005	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
LW	B1	WO 01/053537	7/26/01	WIPO			
LW	B2	WO 99/65928	12/23/99	WIPO			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LW	C1	Buchwald <i>et al.</i> , "Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs," <i>J. Am. Coll. Cardio.</i> , 39(4):732-738, 2002
	C2	Cattaruzza <i>et al.</i> , "The ⁻⁷⁸⁶ variant of the human endothelial nitric oxide synthase gen promoter is a risk factor for coronary heart disease," <i>Pfluegers Archiv. Eur. J. Physiol.</i> , In Abstract P 12-6, 443:S255, 2002.
	C3	Daugherty and Rateri, "T lymphocytes in atherosclerosis: the yin-yang of th1 and th2 influence on lesion formation," <i>Circ. Res.</i> , 90:1039, 2002.
	C4	Dötsch <i>et al.</i> , "Increase of endothelial nitric oxide synthase and endothelin-1 mRNA expression in human placenta during gestation," <i>Eur. J. Ob. Gyn. Reprod. Biol.</i> , 97:163-167, 2001.
	C5	Gimbrone <i>et al.</i> , "Endothelial dysfunction, hemodynamic forces, and atherogenesis ^a ," <i>Ann. N.Y. Acad. Sci.</i> , 920:230, 2000 (Abstract).
	C6	Lienenlücke <i>et al.</i> , "CD154 stimulation of interleukin-12 synthesis in human endothelial cells," <i>Eur. J. Immunol.</i> , 30:2864, 2000.
	C7	Mann <i>et al.</i> , "Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the prevent single-centre, randomised, controlled trial," <i>Lancet</i> , 354: 1493, 1999.

25525390.1

EXAMINER: /Louis Wollenberger/ DATE CONSIDERED: 11/28/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. DEBE:053US	Serial No. 10/527,785
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Marco Cattaruzza Markus Hecker	
		Filing Date: March 11, 2005	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
LW	C8	Marsden <i>et al.</i> , "Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene," <i>J. Biol. Chem.</i> , 268(23):17478-17488, 1993.
	C9	Miyamoto <i>et al.</i> , "Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a-786T→C mutation associated with coronary spastic angina," <i>Hum. Mol. Gene.</i> , 9(18):2629-2637, 2000.
	C10	Moore <i>et al.</i> , "Interleukin-10 and the interleukin-10 receptor," <i>Annu. Rev. Immunol.</i> 19:683-765, 2001.
	C11	Nakayama <i>et al.</i> , "T ⁻⁷⁸⁶ →C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm," <i>Circulation</i> , 9:2684-2870, 1999.
	C12	Stojanovic <i>et al.</i> , "STAT-1 decoy-oligodeoxynucleotide improvement of mucosal perfusion in a rat model of acute transplant rejection," <i>Chirurgisches Forum</i> , 31:275-277, 2002.
	C13	Wagner <i>et al.</i> , "Cytokine-inducible CD40 expresion in human endothelial cells in mediated by interferon regulatory factor-1," <i>Blood</i> , 99(2):520-525, 2002.
	C14	Wattanapitaykul <i>et al.</i> , "Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism," <i>Trends Pharmacol. Sci.</i> , 22:361, 2000, Abstract.

25525390.1

EXAMINER: /Louis Wollenberger/ DATE CONSIDERED: 11/28/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)